Evaxion Biotech AS (EVAX) — Strategic Asset Allocation Index
Evaxion Biotech AS (EVAX) has a Strategic Asset Allocation Index of 23.4% as of June 2022. Strategic assets (PP&E of $4.72 Million plus long-term investments of $-) total $4.72 Million, measured against net assets of $20.15 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Evaxion Biotech AS Strategic Asset Allocation Index (2019–2021)
This chart shows how Evaxion Biotech AS's Strategic Asset Allocation Index has evolved across 3 annual periods from 2019 to 2021. As of June 2022, the index stands at 23.4%, representing strategic assets of $4.72 Million against net assets of $20.15 Million USD. Explore Evaxion Biotech AS (EVAX) cash flow conversion to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Evaxion Biotech AS (2019–2021)
The table below presents the year-by-year Strategic Asset Allocation Index for Evaxion Biotech AS from 2019 to 2021, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see Evaxion Biotech AS market capitalisation.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2021 | 16.0% | $5.17 Million | $5.17 Million | $- | $32.44 Million | ▲ +12.8 pp |
| 2020 | 3.1% | $221.00K | $221.00K | $- | $7.04 Million | ▲ +2.1 pp |
| 2019 | 1.1% | $101.00K | $101.00K | $- | $9.36 Million | — |